Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19 nov. 2024 16h30 HE
|
Abivax
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
17 nov. 2024 10h30 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Abivax presents third quarter 2024 key financial information
14 nov. 2024 16h01 HE
|
Abivax
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
13 nov. 2024 16h01 HE
|
Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq:...
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
09 oct. 2024 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
07 oct. 2024 16h01 HE
|
Abivax
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
03 oct. 2024 02h31 HE
|
Abivax
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
26 sept. 2024 02h30 HE
|
Abivax
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
25 sept. 2024 16h01 HE
|
Abivax
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...
Abivax presents first-half 2024 financial results
09 sept. 2024 16h01 HE
|
Abivax
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA...